Meanwhile, a portfolio of several newer products booked $928 million in sales for the quarter, up 68% from the year-ago period. Bristol Myers said that growth was primarily driven by higher demand, including for prescription anemia medication Reblozyl, which generated $248 million in sales for the quarter.\u00a0<\/p>\n

Skin cancer drug Opdualag also raked in $166 million in sales for the third quarter, which is up 98% from the same quarter a year ago. Those two drugs missed analyst sales estimates compiled by FactSet.\u00a0<\/p>\n

Bristol Myers will hold an earnings call with investors at 8 a.m. E.T. on Thursday.\u00a0<\/p>\n

During the call, executives will likely be asked about the company’s plan to acquire cancer drugmaker Mirati Therapeutics for up to $5.8 billion.<\/p>\n<\/div>\n<\/div>\n\n","protected":false},"excerpt":{"rendered":"

Bristol Myers Squibb on Thursday reported quarterly adjusted earnings that topped expectations and posted revenue in line with estimates, even as sales of the company’s popular blood cancer drug Revlimid plummeted due to generic competition.\u00a0 Bristol Myers, one of the world’s largest pharmaceutical companies, raked in $10.96 billion in revenue for the third quarter, down […]<\/p>\n","protected":false},"author":1,"featured_media":10868,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[44],"tags":[9760,3991,3367,1325,15321,12253,52,199,12207,5360,730,739,15325,15326,528,5552,15322,5553,9759,15323,1065,15324],"class_list":["post-10867","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business","tag-biotech-and-pharmaceuticals","tag-biotechnology","tag-breaking-news","tag-breaking-news-earnings","tag-bristol","tag-bristol-myers-squibb-co","tag-business","tag-business-news","tag-competition","tag-drug","tag-earnings","tag-estimates","tag-fights","tag-generic","tag-health-care-industry","tag-moderna-inc","tag-myers","tag-pfizer-inc","tag-pharmaceuticals","tag-squibb","tag-top","tag-topselling"],"_links":{"self":[{"href":"https:\/\/www.lsd.hu\/wp-json\/wp\/v2\/posts\/10867","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.lsd.hu\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.lsd.hu\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.lsd.hu\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.lsd.hu\/wp-json\/wp\/v2\/comments?post=10867"}],"version-history":[{"count":0,"href":"https:\/\/www.lsd.hu\/wp-json\/wp\/v2\/posts\/10867\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.lsd.hu\/wp-json\/wp\/v2\/media\/10868"}],"wp:attachment":[{"href":"https:\/\/www.lsd.hu\/wp-json\/wp\/v2\/media?parent=10867"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.lsd.hu\/wp-json\/wp\/v2\/categories?post=10867"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.lsd.hu\/wp-json\/wp\/v2\/tags?post=10867"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}